While the most characterized effects of IFNγ during acute disease are primarily pathogenic, the role of IFNγ signaling during chronic stages of MS and in models of neuroinflammation, when the presence of the peripheral immune cells are reduced, remain incompletely understood. The gene discussed is IFNG; the disease is myeloid sarcoma.